407 related articles for article (PubMed ID: 22804236)
21. Heat shock protein 90 inhibition in lung cancer.
Shimamura T; Shapiro GI
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S152-9. PubMed ID: 18520302
[TBL] [Abstract][Full Text] [Related]
22. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways.
Wang H; Sun M; Guo J; Ma L; Jiang H; Gu L; Wen H; Liao S; Chen J; Zeng B; Li Y; Li Y; Yu X; Feng Y; Zhou Y
Biochem Pharmacol; 2017 Jul; 135():35-49. PubMed ID: 28288818
[TBL] [Abstract][Full Text] [Related]
23. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
24. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
25. Hsp90 inhibitors.
Pillai RN; Ramalingam SS
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S407-8. PubMed ID: 23160336
[No Abstract] [Full Text] [Related]
26. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.
Xu XL; Bao QC; Jia JM; Liu F; Guo XK; Zhang MY; Wei JL; Lu MC; Xu LL; Zhang XJ; You QD; Sun HP
Sci Rep; 2016 Jan; 6():19004. PubMed ID: 26743233
[TBL] [Abstract][Full Text] [Related]
27. [Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
Zhang HJ; Zhang XT; Zhang L
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):862-4. PubMed ID: 23324244
[No Abstract] [Full Text] [Related]
28. HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy.
Jafari A; Rezaei-Tavirani M; Farhadihosseinabadi B; Taranejoo S; Zali H
Cancer Invest; 2020 May; 38(5):310-328. PubMed ID: 32274949
[TBL] [Abstract][Full Text] [Related]
29. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
30. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Sang J; Acquaviva J; Friedland JC; Smith DL; Sequeira M; Zhang C; Jiang Q; Xue L; Lovly CM; Jimenez JP; Shaw AT; Doebele RC; He S; Bates RC; Camidge DR; Morris SW; El-Hariry I; Proia DA
Cancer Discov; 2013 Apr; 3(4):430-43. PubMed ID: 23533265
[TBL] [Abstract][Full Text] [Related]
31. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
[TBL] [Abstract][Full Text] [Related]
32. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
33. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
34. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
Graham B; Curry J; Smyth T; Fazal L; Feltell R; Harada I; Coyle J; Williams B; Reule M; Angove H; Cross DM; Lyons J; Wallis NG; Thompson NT
Cancer Sci; 2012 Mar; 103(3):522-7. PubMed ID: 22181674
[TBL] [Abstract][Full Text] [Related]
35. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
36. The Right Tool for the Job: An Overview of Hsp90 Inhibitors.
Koren J; Blagg BSJ
Adv Exp Med Biol; 2020; 1243():135-146. PubMed ID: 32297216
[TBL] [Abstract][Full Text] [Related]
37. Antimyeloma activity of heat shock protein-90 inhibition.
Mitsiades CS; Mitsiades NS; McMullan CJ; Poulaki V; Kung AL; Davies FE; Morgan G; Akiyama M; Shringarpure R; Munshi NC; Richardson PG; Hideshima T; Chauhan D; Gu X; Bailey C; Joseph M; Libermann TA; Rosen NS; Anderson KC
Blood; 2006 Feb; 107(3):1092-100. PubMed ID: 16234364
[TBL] [Abstract][Full Text] [Related]
38. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
